Cardiovascular

Stable angina: outpatient diagnostic workup

Clinical Overview and When to Suspect Stable Angina

— Substernal chest discomfort of characteristic quality and duration

— Provoked by exertion or emotional stress

— Relieved by rest or sublingual nitroglycerin within ~5 minutes

— Typical angina: all 3 features → high pretest probability

— Atypical angina: 2 of 3 → intermediate

— Nonanginal chest pain: ≤1 feature → low

— Middle-aged or older adult with ASCVD risk factors (HTN, DM, dyslipidemia, smoking, family history, CKD) presenting in clinic with exertional discomfort

— Symptoms stable for ≥2 months, no rest pain, no crescendo pattern (otherwise → unstable angina / ACS pathway)

— Anginal equivalents in women, elderly, diabetics: exertional dyspnea, fatigue, epigastric discomfort, jaw/arm pain

Definition: Stable angina is reproducible chest discomfort caused by myocardial oxygen supply–demand mismatch, classically from a fixed atherosclerotic coronary stenosis ≥70% (or ≥50% in the left main).

Core triad (typical/classic angina):

Categorization:

When to suspect on Step 3:

Pathophysiology pearl: Demand ischemia dominates—HR, contractility, wall tension rise with exertion; fixed plaque limits flow reserve. Endothelial dysfunction and microvascular disease (INOCA) cause angina without obstructive CAD, especially in women.

Step 3 management: A patient describing reproducible exertional substernal pressure that resolves with rest belongs in the outpatient stable angina workup track—do NOT send to the ED unless symptoms have changed in frequency, severity, duration, or now occur at rest within the prior 2 months.

Board pearl: The first decision in stable chest pain is risk-stratifying pretest probability using age, sex, and symptom typicality (2021 AHA/ACC/ASE Chest Pain Guideline). This determines whether to test at all, and which test.

Red flags pushing off the stable pathway: rest pain, pain >20 min, syncope with pain, new heart failure signs, dynamic ECG changes, troponin elevation.

Presentation Patterns and Key History

— Exertion (climbing stairs, walking uphill, carrying groceries)

— Cold exposure, large meals, emotional stress, sexual activity

— Reproducibility at a consistent workload is the hallmark of stability

— I: Angina with strenuous exertion only

— II: Slight limitation—angina with walking >2 blocks or >1 flight stairs

— III: Marked limitation—angina with <2 blocks or 1 flight

— IV: Any activity or rest pain

— ASCVD risk factors: HTN, DM, dyslipidemia, tobacco (pack-years), family history of premature CAD (<55 M, <65 F)

— Prior CAD, PCI, CABG, stroke, PAD

— Cocaine/stimulant use, sildenafil/tadalafil use (nitrate contraindication)

— Functional capacity in METs (climbing 2 flights = ~4 METs)

— Bleeding history, prior intolerance to aspirin/statins

Quality: Pressure, squeezing, heaviness, tightness, "elephant on chest." Sharp, stabbing, or pleuritic pain argues against angina.

Location: Substernal, often radiating to left arm, both arms, jaw, neck, epigastrium, or interscapular area. Localized to a fingertip-sized spot = unlikely cardiac.

Duration: Typically 2–10 minutes. <30 seconds or >20 minutes argues against typical stable angina (very brief → musculoskeletal/esophageal; prolonged → consider ACS).

Provocation:

Relief: Rest within minutes; sublingual nitroglycerin within 1–5 minutes. Relief by antacids or position change suggests GERD or musculoskeletal.

Canadian Cardiovascular Society (CCS) class:

Targeted history (Step 3 outpatient visit):

Key distinction: Stable vs unstable angina—unstable = new-onset (<2 months), rest pain, or crescendo pattern (more frequent, longer, lower threshold). Any of these reclassifies the patient to ACS workup with troponin and ED disposition.

Board pearl: A patient whose anginal threshold has dropped from 4 blocks to 1 block over 3 weeks is unstable angina, not stable—even if symptoms still resolve with rest. Disposition: ED, not stress test in clinic.

Anginal equivalents: In diabetics, elderly, women, and post-transplant patients, exertional dyspnea or fatigue may be the only manifestation.

Physical Exam Findings and Hemodynamic Assessment

— BP in both arms (≥15 mmHg difference → consider subclavian stenosis or aortic dissection)

— Resting tachycardia or HTN raises myocardial demand

— Orthostatics if dizziness or on nitrates/antihypertensives

— During angina episode: transient S4 (stiff ischemic ventricle), paradoxically split S2, transient apical systolic murmur of ischemic mitral regurgitation (papillary muscle dysfunction)

— Displaced PMI → LV enlargement/prior MI

— S3 → systolic dysfunction/heart failure

— Carotid bruits, diminished pedal pulses, AAA palpation, femoral bruits

— Ankle-brachial index if PAD suspected

— Reproducible chest wall tenderness → costochondritis (but does NOT rule out CAD)

— Epigastric tenderness → PUD/GERD

— Pleuritic component, pericardial rub → pericarditis

— Tachypnea, unilateral leg swelling → PE

— Pallor, conjunctival rim pallor → anemia

— Tachycardia, lid lag, tremor, warm skin → hyperthyroidism

— Harsh crescendo-decrescendo SEM at RUSB radiating to carotids with delayed upstroke → aortic stenosis (a key mimic causing exertional angina)

— Sustained apical impulse, systolic murmur worsening with Valsalva → HOCM

General rule: The exam in stable angina is often normal between episodes—a normal exam does NOT lower suspicion. Exam is used more to identify risk factors, alternative diagnoses, and comorbid heart failure or valvular disease.

Vitals:

Cardiac exam:

Vascular exam (atherosclerosis is systemic):

Other systems pointing to alternatives:

Findings of secondary causes of angina (supply/demand mismatch):

Hemodynamic clues: elevated JVP, rales, peripheral edema → ischemic cardiomyopathy with HF—changes both workup (echo first) and therapy (avoid negative inotropes initially).

Step 3 management: Always perform a focused AS and HOCM screen before ordering an exercise stress test—severe AS is a relative contraindication, and stress in HOCM can provoke outflow obstruction.

Board pearl: A new systolic murmur during chest pain that disappears at rest is transient ischemic MR—high specificity for active ischemia.

Diagnostic Workup — Initial Labs, ECG, and Baseline Imaging

— Often normal in 50% of stable angina patients—a normal ECG does not exclude CAD

— Look for: pathologic Q waves (prior MI), LVH with strain, LBBB, ST-T abnormalities, conduction disease

— Baseline abnormalities (LBBB, paced rhythm, LVH with strain, WPW, digoxin effect, resting ST depression ≥1 mm) make exercise ECG uninterpretable → choose imaging-based stress

— Lipid panel (fasting or non-fasting)

— Fasting glucose and HbA1c (screen for DM)

— CBC (anemia as supply-side trigger)

— Basic metabolic panel (Cr/eGFR—affects contrast and metformin decisions)

— TSH (hyper- or hypothyroidism)

— Liver enzymes (baseline before statin)

— Consider hsCRP, Lp(a) for risk refinement in selected patients

— Indicated when: prior MI, pathologic Q waves, HF signs, murmur, ventricular arrhythmia, or suspected structural cause (AS, HOCM)

— Assesses LV function (key for prognosis and therapy), wall motion abnormalities, valvular disease

— Not required in every stable angina patient with a normal exam and ECG

— Use PCE (Pooled Cohort Equations) for 10-yr ASCVD risk to guide statin/aspirin

— Use 2021 AHA/ACC pretest probability tables (age, sex, symptom type) to choose next test

Resting 12-lead ECG (every patient):

Initial labs (outpatient panel):

Troponin: Not routine in stable, chronic exertional symptoms. Order if symptoms changed in frequency/severity/duration or occurred at rest within 2 weeks → that's ACS workup.

Chest X-ray: Only if HF, valvular disease, aortic pathology, or pulmonary cause suspected—not routine for stable angina.

Resting transthoracic echocardiogram:

Risk calculators:

CCS pearl: On a CCS case, the initial cluster for outpatient chest pain: ECG, CBC, BMP, lipids, HbA1c, TSH, fasting glucose—then advance to stress or anatomic testing based on pretest probability.

Board pearl: A resting ECG with LBBB or paced rhythm mandates pharmacologic stress with imaging (vasodilator MPI or stress echo with dobutamine)—exercise ECG is uninterpretable and exercise-induced septal motion artifacts limit nuclear too.

Diagnostic Workup — Stress Testing and Coronary Anatomic Imaging

— Preferred in intermediate-risk patients <65 with no prior known CAD (Class 1)

— Excellent negative predictive value—rules out obstructive CAD

— Adds plaque burden info (CAC score, vulnerable plaque)

— Requires HR control (β-blocker to <60), sinus rhythm preferred; limited by severe calcification, obesity, CKD (contrast)

— Exercise ECG alone: Only if able to exercise AND baseline ECG interpretable AND intermediate pretest probability. Achieve ≥85% age-predicted max HR (220 − age).

— Stress echo: Add when ECG uninterpretable or imaging desired; detects wall motion abnormalities; no radiation

— Nuclear MPI (SPECT/PET): Better in obese patients, prior CABG, or when wall motion baseline is abnormal; quantifies ischemic burden

— Cardiac MRI stress: Highest spatial resolution; good for microvascular disease assessment

— Vasodilators (regadenoson, adenosine, dipyridamole) with MPI—avoid in severe asthma/COPD bronchospasm; hold caffeine 12–24 h

— Dobutamine with echo—avoid in serious arrhythmia, severe HTN, recent ACS

— Exercise-induced ST depression ≥2 mm at low workload, hypotension with exertion, ≥10% ischemic myocardium on MPI, multiple wall motion abnormalities at low dose, Duke treadmill score ≤ −11

— Indicated for high-risk noninvasive findings, refractory symptoms despite GDMT, or when revascularization is being considered

— FFR or iFR for intermediate (40–70%) lesions

2021 AHA/ACC Chest Pain Guideline framework: Choose between anatomic (CCTA) and functional (stress) testing based on pretest probability, ECG interpretability, and ability to exercise.

Coronary CT angiography (CCTA):

Functional stress testing (when to choose which):

Pharmacologic stress (cannot exercise or LBBB/paced):

High-risk stress findings (proceed to invasive coronary angiography):

Invasive coronary angiography (ICA):

Key distinction: CCTA answers "is there disease?" (anatomy); stress testing answers "is the disease causing ischemia?" (function). Use anatomy first when ruling out CAD matters most; use function when guiding revascularization.

Board pearl: A 55-year-old woman with atypical chest pain and interpretable ECG: CCTA is now first-line per 2021 guidelines.

Risk Stratification and Management Logic

— Symptom relief (antianginal therapy)

— Event prevention (reduce MI/death—statins, antiplatelets, BP/glucose control, lifestyle)

— LV ejection fraction (echo)

— Extent of CAD on anatomy or ischemic burden on functional testing

— Symptom burden and exercise capacity (METs achieved; Duke treadmill score)

— Comorbidities: DM, CKD, PAD, prior MI

— Left main ≥50%, proximal LAD ≥70%, 3-vessel disease especially with DM

— LVEF <35% with ischemic etiology

— Large ischemic burden (>10% myocardium) on stress imaging

— Lifestyle-limiting angina despite optimal medical therapy (OMT)

— Start with optimal medical therapy in most stable angina patients

— Reserve revascularization for refractory symptoms, high-risk anatomy (left main, severe proximal LAD, 3VD + DM/low EF), or specific subgroups

— Confirm diagnosis (pretest probability → CCTA or stress)

— Risk-stratify (LVEF, ischemic burden, anatomy)

— Initiate dual goals: antianginal + event-prevention drugs

— Lifestyle modification: smoking cessation, Mediterranean diet, 150 min/wk aerobic, weight loss, BP <130/80, LDL <70 (often <55)

— Reassess at 4–6 weeks for symptom control; escalate if angina persists

Two parallel goals after diagnosis:

Prognostic risk stratification drivers:

High-risk features → consider invasive angiography ± revascularization:

ISCHEMIA trial takeaway: In stable CAD with moderate–severe ischemia, initial invasive strategy did NOT reduce death/MI vs OMT, but improved angina and quality of life. Translation for Step 3:

COURAGE trial: PCI in stable CAD did not reduce death/MI vs OMT—reinforces medical therapy first.

Diabetes consideration (FREEDOM trial): For multivessel CAD + DM, CABG > PCI in reducing death/MI/stroke.

Step 3 management algorithm:

Board pearl: Post-ISCHEMIA, the right answer for "stable angina + moderate ischemia + controlled symptoms" is continue OMT, not catheterization—unless high-risk anatomy or refractory symptoms.

Pharmacotherapy — First-Line Drug Regimen

— Aspirin 81 mg daily (clopidogrel 75 mg if true ASA allergy/intolerance)

— High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg); target LDL <70 mg/dL, often <55 for very high risk; add ezetimibe then PCSK9 inhibitor if not at goal

— ACE inhibitor or ARB if HTN, DM, CKD, or LVEF ≤40%

— BP control to <130/80; HbA1c individualized (~7%)

— Consider SGLT2 inhibitor if T2DM with ASCVD (empagliflozin, dapagliflozin—cardiovascular benefit)

— Influenza vaccine annually; pneumococcal and COVID per schedule

— Sublingual nitroglycerin 0.4 mg PRN: for acute episodes; one tablet, repeat q5 min up to 3 doses; call 911 if pain persists after first dose per 2021 AHA. Educate on storage and shelf-life.

— First-line maintenance: β-blocker (metoprolol succinate, bisoprolol, carvedilol)—target resting HR 55–60. Strongly preferred if prior MI or HF with reduced EF.

— Alternative/add-on first-line: long-acting calcium channel blocker

– Non-dihydropyridine (diltiazem, verapamil) if β-blocker contraindicated—avoid combining with β-blocker (bradycardia, heart block)

– Dihydropyridine (amlodipine, long-acting nifedipine) can be added safely to β-blocker

— Long-acting nitrates (isosorbide mononitrate) as add-on; ensure 10–14 h nitrate-free interval to prevent tolerance

— Ranolazine 500–1000 mg BID—useful when HR/BP limit other agents; prolongs QT, contraindicated with strong CYP3A4 inhibitors

— Ivabradine if sinus rhythm and HR >70 despite β-blocker, EF ≤35%

Event prevention ("disease-modifying" drugs)—every patient unless contraindicated:

Antianginal therapy—symptom control:

Second-line / refractory angina:

Critical contraindication: nitrates + PDE5 inhibitors (sildenafil, tadalafil, vardenafil) → life-threatening hypotension. Separate by ≥24 h (sildenafil/vardenafil) or ≥48 h (tadalafil).

Board pearl: β-blockers reduce mortality only in post-MI and HFrEF patients, not in stable angina without these features—but they remain first-line antianginal because they reduce HR × BP product and ischemic burden.

Step 3 management: Combine β-blocker + statin + ASA + ACEi (if indicated) + sublingual NTG PRN as the default starting regimen.

Revascularization Decisions in Stable Angina

— Refractory angina despite optimal medical therapy (≥2 antianginals)

— High-risk noninvasive findings (large ischemic burden, low Duke score, LVEF <35% with ischemia)

— Suspected left main, proximal LAD, or multivessel disease

— Survivor of sudden cardiac death with suspected ischemic substrate

— Angiographic stenosis ≥70% (or ≥50% in left main) generally significant

— FFR ≤0.80 or iFR ≤0.89 confirms hemodynamic significance for intermediate lesions—guides whether to revascularize

— CABG preferred:

– Left main disease (especially complex)

– 3-vessel CAD with SYNTAX score >22

– Multivessel CAD + diabetes (FREEDOM trial)

– LVEF ≤35% with extensive multivessel disease (STICH)

— PCI preferred:

– Single-vessel or focal lesions

– High surgical risk

– Patient preference after shared decision-making

— DAPT after elective PCI for stable CAD with DES: 6 months (can shorten to 1–3 months in high bleeding risk per ARC-HBR criteria, or extend to 12+ months in high ischemic risk)

— Loading dose clopidogrel 600 mg before PCI; maintenance 75 mg daily + ASA 81 mg

— After CABG: ASA lifelong; clopidogrel 1 year if off-pump or for vein graft patency in some protocols

— Class 1 recommendation—reduces mortality, improves QoL

— 36 sessions covered by Medicare

Indications for coronary angiography ± revascularization:

Lesion significance:

PCI vs CABG decision:

Periprocedural antiplatelet therapy:

Cardiac rehabilitation post-revascularization:

Risks to counsel: CIN (pre-hydrate, hold metformin and nephrotoxins, use minimum contrast), bleeding, stent thrombosis (medication adherence critical), restenosis.

CCS pearl: Before scheduling elective PCI, your CCS orders include: type & screen, CBC, BMP/Cr, INR if on warfarin, ECG, hold metformin morning of procedure, IV hydration, clopidogrel/ticagrelor load, ASA 81 mg, statin pretreatment.

Board pearl: A diabetic with 3-vessel disease and stable angina—CABG is the right answer even if PCI is technically feasible (FREEDOM).

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher prevalence of CAD but also more atypical presentations (dyspnea, fatigue, confusion)

— Lower exercise capacity → pharmacologic stress often required

— CCTA caveats: more calcification limits luminal assessment; consider functional testing

— Polypharmacy risk: orthostatic hypotension from nitrates + α-blockers + diuretics; falls risk

— Start low, go slow: lower β-blocker and CCB doses; monitor for bradycardia, AV block

— Statins still beneficial; consider moderate-intensity if frailty or limited life expectancy; shared decision-making

— Aspirin for primary prevention is NOT recommended ≥70, but in established CAD (secondary prevention) ASA is continued lifelong

— Increased ASCVD risk—CKD is a CAD risk equivalent

— Contrast-induced nephropathy: avoid unnecessary CCTA/angio; if needed, isotonic saline pre/post hydration, minimize contrast volume, hold NSAIDs and nephrotoxins, hold metformin 24–48 h before contrast if eGFR <30 or AKI risk

— Avoid gadolinium if eGFR <30 (NSF risk for older agents)

— Dose-adjust: atenolol, sotalol, ranolazine; avoid nitroprusside infusions

— Statins beneficial; rosuvastatin cap at 10 mg if eGFR <30

— ACEi/ARB: monitor K+ and Cr 1–2 weeks after initiation; acceptable Cr rise ≤30%

— Statins generally safe in chronic stable liver disease; avoid in decompensated cirrhosis or acute liver failure; pravastatin/rosuvastatin have less hepatic metabolism

— Ranolazine contraindicated in Child-Pugh B/C

— Metoprolol metabolized hepatically—use cautiously; atenolol/nadolol renally cleared

Elderly (≥75):

Frailty assessment: Use clinical frailty scale; frail elderly with stable angina may derive less benefit from invasive testing—prioritize symptom control and goals of care.

CKD (eGFR <60):

Hepatic impairment:

Step 3 management: For an 80-year-old with stable angina and CKD stage 4 unable to exercise, choose pharmacologic stress echo (no contrast nephrotoxicity, no radiation) over CCTA or nuclear MPI.

Board pearl: In CKD, the most common cause of death is cardiovascular—aggressive statin and BP control matter more than any single antianginal.

Special Populations — Women, Pregnancy, and Younger Adults

— More likely to present with atypical symptoms (fatigue, dyspnea, nausea, jaw pain)

— Higher rates of INOCA (ischemia with non-obstructive coronary arteries), microvascular dysfunction, coronary vasospasm

— Workup pearls:

– CCTA preferred in symptomatic women with low–intermediate pretest probability

– If CCTA shows non-obstructive disease but symptoms persist, consider coronary reactivity testing (acetylcholine provocation) or CMR perfusion for microvascular angina

— Microvascular angina treatment: β-blockers, CCBs, statins, ACEi, ranolazine

— Stable angina in pregnancy is rare but rising with advanced maternal age, ART, chronic HTN, DM

— Diagnostics:

– ECG and echo are safe and first-line

– Avoid CCTA and nuclear when possible (radiation); stress echo preferred

– If angiography needed, abdominal shielding, minimize fluoroscopy

— Drug safety:

– Safe: β-blockers (prefer labetalol, metoprolol; avoid atenolol—IUGR), nitrates, hydralazine, low-dose aspirin (especially after 12 wk; reduces preeclampsia)

– Avoid: ACEi/ARB/ARNI (teratogenic—renal dysgenesis, oligohydramnios), statins (historically contraindicated, though FDA removed blanket contraindication in 2021—still avoid unless clear benefit), amiodarone

– Clopidogrel: limited data; use only if essential

— Cocaine/stimulant use (avoid β-blockers acutely; use CCB, nitrates)

— Vasospastic (Prinzmetal) angina—rest pain, often nocturnal, transient ST elevation; treat with CCB ± nitrates; avoid β-blockers (unopposed α-vasoconstriction)

— Familial hypercholesterolemia (LDL >190, premature CAD family history)—high-intensity statin + ezetimibe + PCSK9 inhibitor; cascade screen family

— SCAD (spontaneous coronary artery dissection)—peripartum women; usually managed conservatively

— Anomalous coronary arteries, Kawasaki sequelae

Women with stable angina:

Pregnancy:

Younger adults (<45) with stable angina—think beyond classic atherosclerosis:

Key distinction: Vasospastic angina is provoked by rest/cold/hyperventilation and relieved by CCBs, not β-blockers, which may worsen spasm.

Board pearl: A pregnant patient with chronic HTN and exertional chest pain—stop ACEi immediately, switch to labetalol, get echo, defer CCTA.

Complications and Adverse Outcomes

— Stable plaque rupture → ACS (unstable angina, NSTEMI, STEMI)—risk highest with inflammation, hypertension, ongoing smoking, untreated dyslipidemia

— Progressive ischemic cardiomyopathy → HFrEF

— Ventricular arrhythmias from ischemic scar → sudden cardiac death

— Ischemic mitral regurgitation

— LV thrombus and embolic stroke (post-MI, low EF)

— β-blockers: bradycardia, AV block, fatigue, depression, bronchospasm (in reactive airway disease—prefer cardioselective β1: bisoprolol, metoprolol), masking hypoglycemia in DM

— Nitrates: headache (very common, often improves over days), hypotension, syncope; tolerance if no nitrate-free interval; lethal hypotension with PDE5 inhibitors

— CCBs: peripheral edema (amlodipine), constipation (verapamil), gingival hyperplasia, bradycardia/heart block (non-DHP)

— Statins: myalgia, transaminitis, rare rhabdomyolysis, modest new-onset DM, drug interactions (especially simvastatin with CYP3A4 inhibitors)

— Aspirin: GI bleed, peptic ulcer, hemorrhagic stroke—co-prescribe PPI if high bleed risk (age >65, NSAIDs, anticoagulation, H. pylori, prior GI bleed)

— Ranolazine: QT prolongation, constipation, dizziness

— Clopidogrel: bleeding, rare TTP

— Stent thrombosis (acute, subacute, late, very late)—premature DAPT discontinuation is the leading modifiable cause

— In-stent restenosis

— Contrast nephropathy

— Access-site complications (hematoma, retroperitoneal bleed, pseudoaneurysm)

— Coronary perforation, MI, stroke

Disease progression:

Medication-related complications:

Procedural complications (post-PCI):

Quality-of-life burden: Persistent angina despite OMT—consider EECP (enhanced external counterpulsation), spinal cord stimulation, or referral for refractory angina program.

Step 3 management: A stable angina patient on β-blocker + nitrate with HR 50 and lightheadedness—don't add more antianginal; reduce β-blocker dose first, reassess in 2 weeks. If angina recurs, add ranolazine (HR/BP-neutral) rather than another HR-lowering agent.

Board pearl: A patient stops clopidogrel 4 months after DES placement for a tooth extraction and develops STEMI—late stent thrombosis from premature DAPT cessation. Always coordinate with cardiology before stopping antiplatelets.

When to Escalate Care — ED, Inpatient, and Consult Triggers

— New rest pain

— Anginal episodes increasing in frequency, severity, duration, or occurring at lower thresholds (crescendo)

— Pain lasting >20 minutes

— Syncope or near-syncope with chest pain

— New dyspnea, orthopnea, PND suggesting HF

— New ECG changes (ST depression, T-wave inversion) compared with baseline

— High-risk noninvasive findings (large ischemic burden, low Duke score, LVEF <35%)

— Refractory angina despite ≥2 optimal-dose antianginals

— Suspected left main, multivessel, or proximal LAD disease

— Suspected vasospastic angina needing provocation testing

— INOCA workup (microvascular dysfunction)

— Pre-revascularization decision-making (Heart Team for complex anatomy)

— Left main disease

— Complex multivessel disease (SYNTAX score >22)

— Diabetes with multivessel CAD

— LVEF ≤35% with multivessel disease

— Suspected ACS (troponin pending, evolving symptoms)

— Hemodynamic instability

— Heart failure decompensation

— High-risk arrhythmia (sustained VT, complete heart block)

— Need for urgent invasive workup not feasible outpatient

— Cardiogenic shock

— Refractory ischemia despite IV therapy

— Mechanical complications (acute MR, VSR, free wall rupture)

— Sustained VT/VF

— Post-arrest care

— Use ACC/AHA stepwise algorithm; if functional capacity ≥4 METs and asymptomatic, proceed without further testing

— If poor functional capacity, use RCRI; pursue stress testing only if results would change management

From stable to unstable—immediate ED referral:

Cardiology consult (outpatient or urgent):

Heart Team referral (cardiology + cardiac surgery):

Inpatient admission criteria:

ICU triggers:

Pre-procedure preoperative cardiac evaluation:

CCS pearl: A patient calls reporting that nitroglycerin no longer relieves pain at home—EMS to ED, not clinic. This is the classic transition trigger from stable to acute coronary syndrome.

Board pearl: A patient with stable angina scheduled for hip replacement with functional capacity <4 METs and 2 RCRI factors → noninvasive stress test only if it changes perioperative management; otherwise proceed with β-blocker continuation and statin.

Key Differentials — Other Cardiovascular Causes of Chest Pain

— Rest pain, crescendo pattern, prolonged duration, dynamic ECG changes, troponin elevation

— Disposition: ED, not outpatient workup

— Young to middle-aged, often smokers; rest pain, often nocturnal/early morning

— Transient ST elevation during episode that resolves

— Diagnosis: ambulatory ECG, ergonovine or acetylcholine provocation

— Treatment: CCB (diltiazem, amlodipine) ± long-acting nitrates; avoid β-blockers

— Typical anginal symptoms, ischemia on imaging, normal epicardial arteries

— More common in women

— Treatment: β-blockers, ACEi, statin, ranolazine; address risk factors

— Triad: angina, syncope, heart failure

— Harsh crescendo-decrescendo SEM, late peaking, with carotid radiation and parvus et tardus pulse

— Echo diagnostic; avoid vigorous exercise testing in severe AS

— Exertional angina, dyspnea, syncope; family history of sudden death

— Murmur worsens with Valsalva/standing, decreases with squat/handgrip

— Echo with LVOT gradient; treatment β-blocker, disopyramide, septal reduction in select; avoid nitrates, ACEi (preload reducers)

— Sharp pleuritic pain, worse supine, relieved sitting forward; pericardial rub

— Diffuse ST elevation with PR depression; treat NSAIDs + colchicine

— Sudden tearing chest/back pain, BP differential, widened mediastinum on CXR

— CT angiography aorta; emergency

— Exertional dyspnea may mimic anginal equivalent

— Echo, BNP differentiate

— AF with RVR, sustained SVT can produce demand ischemia in patients with limited coronary reserve

Acute coronary syndrome (unstable angina, NSTEMI, STEMI):

Vasospastic (Prinzmetal/variant) angina:

Microvascular angina (INOCA):

Aortic stenosis:

Hypertrophic obstructive cardiomyopathy (HOCM):

Pericarditis:

Aortic dissection:

Heart failure with reduced ejection fraction:

Tachyarrhythmia-induced ischemia:

Key distinction: Aortic stenosis vs stable angina—both cause exertional chest pain in elderly, but AS produces syncope and a classic murmur; stress testing is contraindicated in severe symptomatic AS. Always auscultate before ordering exercise stress.

Board pearl: Recurrent chest pain at rest in a 35-year-old smoker with normal coronaries on CCTA and transient ST elevation captured on Holter—vasospastic angina; start a CCB, stop smoking, and never start a β-blocker.

Key Differentials — Non-Cardiac Causes of Chest Pain

— GERD: burning retrosternal pain, postprandial, supine worsening, relief with antacids; PPI trial both diagnostic and therapeutic

— Esophageal spasm: mimics angina closely, can even respond to nitrates—requires manometry to diagnose

— Peptic ulcer disease: epigastric, food-related; EGD if alarm features

— Biliary colic: RUQ/epigastric, postprandial, fatty food trigger; ultrasound

— Pancreatitis: epigastric to back, elevated lipase

— Pulmonary embolism: pleuritic chest pain, dyspnea, tachycardia, hypoxia, unilateral leg swelling; Wells score → D-dimer or CTPA

— Pneumonia: fever, productive cough, focal CXR findings

— Pneumothorax: sudden pleuritic pain, decreased breath sounds, hyperresonance

— Pleuritis: sharp, pleuritic, often viral

— Pulmonary hypertension: exertional dyspnea, chest pain, syncope

— Costochondritis (Tietze): reproducible chest wall tenderness, well-localized; NSAIDs

— Cervical or thoracic radiculopathy

— Rib fracture, intercostal strain

— Reproducibility on palpation does not rule out CAD (~10% of MI patients have reproducible pain)

— Panic disorder: chest pain with palpitations, dyspnea, fear of dying, paresthesias; up to 25% of ED chest pain

— Anxiety, depression can coexist with and amplify true CAD symptoms

— Herpes zoster: prodromal dermatomal pain before rash

— Costosternal syndrome, slipping rib syndrome

— Mediastinal masses

Gastrointestinal (most common non-cardiac mimic):

Pulmonary:

Musculoskeletal:

Psychiatric:

Other:

Step 3 management: When chest pain is reproduced on palpation AND the patient has multiple ASCVD risk factors, don't anchor on costochondritis—still risk-stratify with ECG and consider CCTA or stress per pretest probability.

Key distinction: GERD vs angina—both can improve with nitroglycerin (smooth muscle relaxation), so nitro response is not specific. Use exertional pattern, risk factors, and objective testing.

Board pearl: A patient with chest pain that radiates around the back in a dermatomal pattern, then develops vesicles 3 days later—herpes zoster, classic mimic of anginal radiation in elderly.

Secondary Prevention and Long-Term Outpatient Plan

— A: Antiplatelet (aspirin 81 mg lifelong; clopidogrel 75 mg if ASA intolerant); ACE inhibitor/ARB if HTN, DM, CKD, or LVEF ≤40%; Anginal control with antianginals

— B: β-blocker if prior MI or HFrEF (mortality benefit); BP <130/80

— C: Cholesterol—high-intensity statin, LDL <70 (often <55 in very high risk); add ezetimibe → PCSK9 inhibitor; Cigarette cessation (single highest-yield intervention); Cardiac rehab

— D: Diet (Mediterranean or DASH); Diabetes control (HbA1c ~7%, individualized); consider SGLT2 inhibitor or GLP-1 RA in T2DM with ASCVD

— E: Exercise 150 min/wk moderate aerobic + 2 days resistance; Education about NTG use, when to call 911

— LDL <70 mg/dL (post-ACS or very high risk: <55)

— BP <130/80

— HbA1c ~7% (relax to 7.5–8% in frail elderly, limited life expectancy)

— BMI toward 18.5–24.9

— Icosapent ethyl (Vascepa) 2 g BID: if TG 135–499 on statin with ASCVD (REDUCE-IT)

— Bempedoic acid: statin-intolerant patients

— Colchicine 0.5 mg daily: considered in select patients with recurrent events (LoDoCo2)

— Annual influenza (Class 1 in CAD)

— Pneumococcal per age/risk schedule

— COVID-19 boosters per CDC

— RSV for ≥75 or 60–74 with comorbidities

— Smoking cessation: offer behavioral support + varenicline (preferred) or NRT or bupropion at every visit; CAD itself is not a contraindication to varenicline

— Alcohol: ≤1 drink/day women, ≤2 men

— Sleep apnea screening if obese, snoring, HTN, AF

— Sexual activity counseling: generally safe if can climb 2 flights; PDE5 inhibitors OK if not on nitrates

The "ABCDE" framework for chronic stable CAD:

Specific pharmacotherapy targets:

Newer agents to consider:

Vaccinations:

Lifestyle counseling specifics:

Step 3 management: At every visit, ask about angina frequency, NTG use, medication adherence, side effects, and lifestyle adherence. Document a goals-of-care discussion at least annually in elderly/frail patients.

Board pearl: Smoking cessation alone reduces all-cause mortality ~36% in CAD patients—larger than any single drug.

Follow-Up, Monitoring Parameters, and Cardiac Rehabilitation

— Initial diagnosis: follow-up at 4–6 weeks to assess symptom control, medication tolerance, side effects, BP, HR

— Stable: every 6–12 months

— Post-revascularization: 2–4 weeks, then 3, 6, 12 months

— Worsening symptoms: prompt visit; if change suggests instability → ED

— Anginal frequency, threshold, NTG tablet use per week

— CCS class

— Medication adherence, side effects

— BP, HR, weight, BMI

— Tobacco/alcohol use, physical activity

— Depression and anxiety screening (PHQ-2/GAD-2)

— Lipid panel: 4–12 weeks after starting/changing statin, then every 3–12 months

— LFTs: baseline; repeat only if symptomatic (no routine surveillance unless symptoms)

— CK: only if myalgia/weakness suggests myopathy

— HbA1c: every 3–6 months in DM

— Renal function and K+: 1–2 weeks after starting/uptitrating ACEi/ARB/spironolactone, then periodically

— CBC: if on antiplatelets and bleeding suspected

— Routine repeat stress testing in asymptomatic patients is not recommended

— Repeat testing only if symptoms recur or change

— Echo if HF symptoms develop or after MI to reassess EF

— Class 1 indication post-MI, post-PCI, post-CABG, stable angina, HF

— 36 sessions, 3×/week × 12 weeks; Medicare-covered

— Reduces mortality 20–30%, improves exercise capacity, mental health, adherence

— Underutilized—especially in women, minorities, elderly—make active referrals

— How to use sublingual NTG (sit down, one tab, wait 5 min, repeat ×2, call 911 if persists after first dose per 2021 AHA)

— Symptom diary

— Recognize ACS warning signs

— Medication adherence strategies (pillbox, apps, family support)

Visit cadence:

At each visit, document:

Laboratory monitoring:

Imaging follow-up:

Cardiac rehabilitation:

Patient education essentials:

Step 3 management: A patient on stable regimen reports 1–2 NTG uses per month for predictable activities—that's controlled stable angina; continue current regimen, reinforce lifestyle, no new testing.

Board pearl: Cardiac rehab referral at hospital discharge is a CMS quality measure—miss it on a CCS case and you'll lose points.

Ethical, Legal, and Patient Safety Considerations

— Disclose risks (bleeding, stroke, MI, contrast nephropathy, death ~0.1%), alternatives (OMT, CABG), and post-ISCHEMIA evidence that elective PCI does not reduce death/MI in stable CAD

— Document shared decision-making—patient values around symptom relief vs procedural risk drive the decision

— Delay elective non-cardiac surgery for at least 6 months after DES in stable CAD (1 month minimum, 3 months if urgent semi-elective)

— Always coordinate antiplatelet management with cardiologist + surgeon + anesthesia—premature DAPT cessation is a leading cause of stent thrombosis

— For urgent surgery: continue aspirin if possible; stop P2Y12 inhibitor 5–7 days preop (clopidogrel/ticagrelor 5, prasugrel 7)

— Hospital discharge after PCI: medication reconciliation, written DAPT duration plan, follow-up appointment within 1–2 weeks, communication to PCP

— Missed cardiac rehab referrals and lapses in statin/DAPT at discharge are leading patient-safety failures

— Generally safe to drive with stable angina if symptoms controlled

— Commercial drivers (CDL) and pilots have FAA/FMCSA-specific clearances after revascularization or symptom changes

— Counsel: do not drive during an active anginal episode; pull over if NTG used

— Most states do not require reporting of CAD; however, if syncope occurs at the wheel or arrhythmia causes impairment, report per state law (varies)

— Women, Black, Hispanic, and low-income patients are less likely to receive timely stress testing, statins, and cardiac rehab—actively address disparities

— Cost barriers to PCSK9 inhibitors, SGLT2s, GLP-1s: use patient assistance programs

— In frail elderly or limited life expectancy, deprescribing statins and aggressive antianginals may be appropriate—use shared decision-making and discuss POLST/advance directives

Informed consent for invasive testing/PCI:

DAPT and surgical planning:

Transition-of-care risk (high-yield Step 3):

Driving and occupational considerations:

Mandatory reporting and disclosure:

Health equity and access:

End-of-life and goals of care:

Step 3 management: A patient with DES placed 2 months ago needs urgent cholecystectomy—continue aspirin, hold clopidogrel 5 days with surgeon/cardiology agreement, bridge plan if very high stent thrombosis risk, resume P2Y12 ASAP postop.

Board pearl: Never stop DAPT in the first month after DES for elective procedures—defer the procedure instead.

High-Yield Associations and Rapid-Fire Clinical Facts

Levine's sign (clenched fist on chest) → classic angina gesture

Diabetics and elderly → silent ischemia and atypical presentations common

Cocaine-induced chest pain → use benzodiazepines, nitrates, CCBs; avoid β-blockers acutely (unopposed α-stimulation)

Vasospastic angina → preserved coronary anatomy, treat with CCB, avoid β-blockers and triptans

Microvascular angina → normal coronaries, ischemia on stress; women predominantly

Aortic stenosis + angina → 50% mortality at 5 years without valve replacement

HOCM → murmur ↑ with Valsalva/standing; avoid preload reducers (nitrates, ACEi, diuretics, dehydration)

PDE5 inhibitor + nitrate → catastrophic hypotension; wait ≥24 h (sildenafil/vardenafil), ≥48 h (tadalafil)

Nitrate tolerance → maintain 10–14 h nitrate-free interval

Ranolazine → no HR or BP effect; useful when those are limiting; prolongs QT

Ivabradine → only in sinus rhythm, HR >70, EF ≤35%; If channel blocker

Aspirin + clopidogrel duration after elective DES for stable CAD → 6 months (modifiable: 1–3 mo if high bleed, 12+ mo if high ischemic risk)

CABG > PCI for: left main, 3VD with high SYNTAX, multivessel + DM (FREEDOM), multivessel + low EF (STICH)

ISCHEMIA trial → invasive strategy did not reduce death/MI in stable CAD with moderate–severe ischemia; improved angina/QoL

Statin myalgia work-up → check CK and TSH, hold and rechallenge, switch agent, consider every-other-day rosuvastatin/pravastatin

High-intensity statins → atorvastatin 40–80, rosuvastatin 20–40 (≥50% LDL reduction)

LDL target in ASCVD → <70 mg/dL; <55 in very high risk (recurrent events, polyvascular)

Duke treadmill score → ≤−11 high risk; ≥+5 low risk

Pretest probability → 2021 AHA/ACC tables (age, sex, symptom typicality) drive testing choice

CCTA → first-line in intermediate-risk patients <65 without known CAD

Smoking cessation → single highest-impact intervention; offer varenicline first-line

Cardiac rehab → mortality reduction 20–30%; underused; refer every eligible patient

Influenza vaccine in CAD → reduces cardiac events

CCS pearl: On every stable CAD CCS scenario, order ASA, statin, β-blocker, ACEi (if indicated), SL NTG, cardiac rehab referral, smoking cessation counseling, and lipid panel follow-up at 4–12 weeks.

Board Question Stem Patterns

— 55 y/o man, atypical chest pain, normal ECG, can exercise → exercise ECG (if interpretable) or CCTA

— Same patient with LBBB → pharmacologic stress with imaging (vasodilator MPI or dobutamine echo)

— Cannot exercise, severe asthma → dobutamine stress echo (avoid vasodilators)

— Young woman, atypical symptoms, normal ECG → CCTA

— Newly diagnosed stable angina → β-blocker + ASA + high-intensity statin + sublingual NTG PRN ± ACEi

— β-blocker contraindicated (severe asthma, bradycardia) → non-DHP CCB (diltiazem)

— Already on β-blocker with persistent angina → add long-acting nitrate or DHP CCB (amlodipine)

— Still symptomatic on multiple agents → ranolazine

— Stable angina + DM + 3-vessel CAD → CABG (FREEDOM)

— Left main 60% stenosis → CABG (or PCI per Heart Team)

— Moderate ischemia on MPI with controlled symptoms on OMT → continue OMT (ISCHEMIA)

— Stable angina + erectile dysfunction taking sildenafil → do NOT prescribe nitrates within 24 h

— Vasospastic angina → avoid β-blockers

— HOCM with angina → avoid nitrates and ACEi (preload reducers worsen obstruction)

— Severe symptomatic AS → avoid exercise stress testing; get echo

— LDL 95 on atorvastatin 40 with established CAD → uptitrate to 80, then add ezetimibe, then PCSK9 inhibitor to reach <70 (or <55)

— Stable CAD + T2DM with HbA1c 8 → add SGLT2 inhibitor or GLP-1 RA with CV benefit

— Post-PCI patient 4 months out needing elective surgery → defer surgery until 6-month DAPT complete

— Stable angina patient now reports rest pain → send to ED for ACS workup, not stress test

— Anginal threshold dropped from 4 to 1 block → unstable angina → ED

Pattern 1 — "Which test next?":

Pattern 2 — "Best initial therapy":

Pattern 3 — "Refer for revascularization":

Pattern 4 — Avoidance traps:

Pattern 5 — Long-term management:

Pattern 6 — Symptom change:

Step 3 management: Always identify whether the vignette is asking about diagnosis, symptom control, event prevention, or escalation—the right answer differs.

Board pearl: When the stem includes "moderate ischemia," "symptoms controlled on medications," and asks next step → choose continue medical therapy (ISCHEMIA-informed answer).

One-Line Recap

Stable angina is reproducible, exertional ischemic chest discomfort whose outpatient workup centers on pretest probability–driven testing (CCTA or stress) and whose management combines symptom control (β-blocker, nitrates, CCBs ± ranolazine) with aggressive event prevention (high-intensity statin, aspirin, ACEi when indicated, lifestyle/risk-factor optimization), reserving revascularization for high-risk anatomy or refractory symptoms.

— Symptoms: β-blocker first-line; add long-acting nitrate or DHP CCB; ranolazine if HR/BP-limited

— Events: ASA 81 + high-intensity statin (LDL <70, often <55) + ACEi if HTN/DM/CKD/EF ≤40 + SGLT2/GLP-1 in T2DM with ASCVD + smoking cessation + cardiac rehab

— Vasospastic angina → CCB, avoid β-blockers

— HOCM angina → avoid nitrates/ACEi

— AS angina → echo, avoid stress test if severe

— Diabetic multivessel CAD → CABG (FREEDOM)

— Stable CAD + moderate ischemia + controlled symptoms → OMT (ISCHEMIA)

— Post-DES → 6 mo DAPT; defer elective surgery; never stop antiplatelets without cardiology

Workup: Resting ECG + targeted labs (lipids, A1c, CBC, BMP, TSH); choose CCTA (anatomy, low–intermediate risk, <65) vs functional stress (ischemia burden, prior CAD, post-revasc); reserve invasive angiography for high-risk findings or refractory symptoms.

Treatment goals are dual:

Special situations to memorize:

Escalation triggers: rest pain, crescendo symptoms, >20-min episodes, syncope, new ECG changes, NTG no longer relieves → ED for ACS pathway, not outpatient stress test.

Board pearl: The two highest-yield Step 3 reflexes—(1) match the diagnostic test to pretest probability AND ECG/exercise capability, and (2) start every stable angina patient on ASA + statin + β-blocker + SL NTG + ACEi-if-indicated unless contraindicated—answer most stems correctly.